Hot Sale Supply Valganciclovir Hydrochloride Powder CAS 175865-59-5 with Safe Delivery CAS NO.175865-59-5
- FOB Price: USD: 50.00-50.00 /Kilogram Get Latest Price
- Min.Order: 1 Kilogram
- Payment Terms: T/T,Other
- Available Specifications:
Top quality(1-10)Kilogram
- Product Details
Keywords
- Valganciclovir Hydrochloride
- 175865-59-5
- Pharmaceutical Intermediates
Quick Details
- ProName: Hot Sale Supply Valganciclovir Hydroch...
- CasNo: 175865-59-5
- Molecular Formula: C14H23ClN6O5
- Appearance: White powder
- Application: Valganciclovir hydrochloride?is used f...
- DeliveryTime: 10-12 days
- PackAge: bag
- Port: shanghai
- ProductionCapacity: 10 Kilogram/Day
- Purity: 99%
- Storage: 2-8℃
- Transportation: air
- LimitNum: 1 Kilogram
Superiority
purity min99%
Large volume discount
Our advantage:
We have PEPTIDES and SARMS WAREHOUSE IN USA and Euro, you can receive order with 3 days without any customs problems.
We offer drop ship to your end clients in worldwide.
Why Choose us:
1). We have our own GMP lab .
2). Warehouses in USA and Euro to support your urgent need.
3). We can customize Peptides and Test Report HPLC and MS are available.
4). / Bank Transfer / Credit Card / Bitcoin / T/T in Advance / LC @ SIGHT / Paypal for your option.
Details
- Product description
Product name |
Valganciclovir hydrochloride |
CAS No. |
175865-59-5 |
Molecular Formula |
C14H23ClN6O5 |
Molecular weight |
390.82 |
Grade Standard |
Medicine Grade |
COA |
Avaliable |
- Product introduction
Valganciclovir hydrochloride, a prodrug of the antiviral ganciclovir, was launched in the US for the oral treatment of cytemegalovirus (CMV) retinitis, a sight-threatening complication in patients with AIDS. Valganciclovir is well absorbed and rapidly hydrolyzed to ganciclovir by intracellular esterases in the intestinal mucosal cells and by hepatic esterases. Unlike ganciclovir, valganciclovir was demonstrated to be actively transported by the intestinal peptide transporter PEPT1 in Caco-2 cells. As a consequence, its absolute bioavailability in human was 10-fold higher compared to ganciclovir (6%). In clinical trials, it was shown that a twice-daily 900 mg dose of valganciclovir resulted in similar systemic ganciclovir exposure to 5 mg/kg twice-daily intravenous injection of ganciclovir. Valganciclovir concentrations could not be quantified in most patients within three to four hours. In a randomized non-blind phase III clinical trial, oral valganciclovir (900 mg twice daily for three weeks then 900 mg once daily for one week) was as effective as intravenous ganciclovir (5 mg/kg twice daily for three weeks then 5 mg/kg once daily). Oral treatment with valganciclovir avoided catheter-related infection that sometimes occurred with intravenous ganciclovir.